Mitchell Schnall, MD, discusses the synergy between the Penn Precision Medicine program and the Department of Radiology in measuring the patient phenotype and in the cooperative effort to define, label and track cancer cell receptors that may contribute to treatment efficacy. Chairman of the Department of Radiology at Penn Medicine, Dr. Schnall also reflects upon the character of genomic testing and the evolution of new therapies for cancer and other serious diseases.